The US Food and Drug Administration approved 40 cancer therapies between January 2010 and December 2014.
How many of those drugs received patient-reported outcomes labeling?
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...